President Trump signed the RACE for Children Act into law on August 18, 2017 as part of the larger FDA Reauthorization Act.
The Research to Accelerate Cures and Equity (RACE) for Children Act will expand and improve the treatment options available to children with cancer by requiring that new adult oncology drugs are also tested on children when the molecular targets are relevant to a particular pediatric cancer. It’s expected that the RACE Act will result in a significant increase in pediatric cancer clinical research and new therapies for childhood cancer, which remains the leading disease killer of American children.
RACE Act provisions evolved from a working group in 2015-2016 and subsequent blueprint report shepherded by members of CAC2 and the Alliance for Childhood Cancer, marking a truly collaborative and effective process.
The need: The RACE Act is in the final sprint. We must ask Congress to attach the RACE Act to the PDUFA Act some time before Congress passes PDUFA in June 2017.